Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Investment Securities: 2015-2025

Historic Gains from Investment Securities for Adma Biologics (ADMA) over the last 5 years, with Mar 2025 value amounting to $1.7 million.

  • Adma Biologics' Gains from Investment Securities was N/A to $1.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $1.7 million, marking a year-over-year change of. This contributed to the annual value of $17,000 for FY2023, which is 98.58% down from last year.
  • According to the latest figures from Q1 2025, Adma Biologics' Gains from Investment Securities is $1.7 million, which was up 165,745.80% from $1,000 recorded in Q4 2023.
  • In the past 5 years, Adma Biologics' Gains from Investment Securities registered a high of $1.7 million during Q1 2025, and its lowest value of $1,000 during Q4 2023.
  • In the last 2 years, Adma Biologics' Gains from Investment Securities had a median value of $8,000 in 2023 and averaged $418,864.
  • As far as peak fluctuations go, Adma Biologics' Gains from Investment Securities tumbled by 99.38% in 2022, and later rose by 11.84% in 2023.
  • Over the past 4 years, Adma Biologics' Gains from Investment Securities (Quarterly) stood at $8,493 in 2021, then climbed by 2.66% to $8,719 in 2022, then crashed by 88.53% to $1,000 in 2023, then reached $1.7 million in 2025.
  • Its Gains from Investment Securities stands at $1.7 million for Q1 2025, versus $1,000 for Q4 2023 and $6,000 for Q2 2023.